Kevin J. Anderson

Kevin J. Anderson

Auto-generated profile, based on publicly available information

Kevin J. Anderson

The Jackson Laboratory for Genomic Medicine, Farmington, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KJKevin C. Johnson
Kevin C. Johnson
KAKevin J. Anderson
Kevin J. Anderson
ECElise Courtois
Elise Courtois
AGAmit D. Gujar
Amit D. Gujar
FBFloris Barthel
Floris Barthel
RVRoel G. W. Verhaak
Roel G. W. Verhaak

9 May 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MNMasashi Nomura
Masashi Nomura
ASAvishay Spitzer
Avishay Spitzer
KJKevin C. Johnson
Kevin C. Johnson
LGLuciano Garofano
Luciano Garofano
DNDjamel Nehar-Belaid
Djamel Nehar-Belaid
ITItay Tirosh
Itay Tirosh
In isocitrate dehydrogenase wildtype glioblastoma (GBM), cellular heterogeneity across and within tumors may drive therapeutic resistance. Here we analyzed 121 primary and recurrent GBM samples from 59 patients using single-nucleus RNA sequencing and bulk tumor DNA sequencing to characterize GBM transcriptional heterogeneity. First, GBMs can be classified by their broad cellular composition, encompassing malignant and nonmalignant cell types. Second, in each cell type we describe the diversity of cellular states and their pathway activation, particularly an expanded set of malignant cell states, including glial progenitor cell-like, neuronal-like and cilia-like. Third, the remaining variation between GBMs highlights three baseline gene expression programs. These three layers of heterogeneity are interrelated and partially associated with specific genetic aberrations, thereby defining three stereotypic GBM ecosystems. This work provides an unparalleled view of the multilayered transcriptional architecture of GBM. How this architecture evolves during disease progression is addressed in the companion manuscript by Spitzer et al.

27 May 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
EKEmre Kocakavuk
Emre Kocakavuk
KAKevin J. Anderson
Kevin J. Anderson
FVFrederick Varn
Frederick Varn
KJKevin C. Johnson
Kevin C. Johnson
SASamirkumar B. Amin
Samirkumar B. Amin
RVRoel G. W. Verhaak
Roel G. W. Verhaak

9 May 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ASAvishay Spitzer
Avishay Spitzer
KJKevin C. Johnson
Kevin C. Johnson
MNMasashi Nomura
Masashi Nomura
LGLuciano Garofano
Luciano Garofano
DNDjamel Nehar-Belaid
Djamel Nehar-Belaid
MSMario L. Suvà
Mario L. Suvà
The evolution of isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GBM) after standard-of-care therapy remains poorly understood. Here we analyzed matched primary and recurrent GBMs from 59 patients using single-nucleus RNA sequencing and bulk DNA sequencing, assessing the longitudinal evolution of the GBM ecosystem across layers of cellular and molecular heterogeneity. The most consistent change was a lower malignant cell fraction at recurrence and a reciprocal increase in glial and neuronal cell types in the tumor microenvironment (TME). The predominant malignant cell state differed between most matched pairs, but no states were exclusive or highly enriched in either time point, nor was there a consistent longitudinal trajectory across the cohort. Nevertheless, specific trajectories were enriched in subsets of patients. Changes in malignant state abundances mirrored changes in TME composition and baseline profiles, reflecting the co-evolution of the GBM ecosystem. Our study provides a blueprint of GBM’s diverse longitudinal trajectories and highlights the treatment and TME modifiers that shape them.

1 July 1999 in Neuroscience
Verified
Journal Article
Closed access
AMA.J. MacLennan
A.J. MacLennan
BDB.K. Devlin
B.K. Devlin
KNK.L. Neitzel
K.L. Neitzel
DMD.L. McLaurin
D.L. McLaurin
KAK.J. Anderson
K.J. Anderson
NLN. Lee
N. Lee

1 December 2017 in Mathematical Biosciences
Verified
Journal Article
Closed access
KAKevin J. Anderson
Kevin J. Anderson
AGAdelaide de Guillebon
Adelaide de Guillebon
AHAndrew D. Hughes
Andrew D. Hughes
WWWeiwei Wang
Weiwei Wang
MKMichael King
Michael King